Analyzing Fulcrum Therapeutics’s Unusual Options Activity
On Tuesday, shares of Fulcrum Therapeutics (NASDAQ:FULC) saw unusual options activity. After the option alert, the stock price moved up to $15.81.
Mid-Morning Market Update: Markets Open Higher; Sysco Tops Q4 Views
Following the market opening Tuesday, the Dow traded up 0.47% to 35,266.74 while the NASDAQ rose 0.04% to 14,866.20. The S&P also rose, gaining 0.28% to 4,444.54.
Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Early-Stage Study
Fulcrum Therapeutics Inc (NASDAQ:FULC) has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers. FTX-6058…
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
Fulcrum Therapeutics Q2 EPS $(0.60) Beats $(0.62) Estimate, Sales $4.40M Up From $2.00M YoY
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.62) by 3.23 percent. This is a 9.09 percent increase over losses of $(0.66) per share
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
Achieved dose proportional pharmacodynamic changes in HBG mRNA and F-reticulocytes in whole blood
Mean 4.5-fold induction in HBG mRNA at 10mg after 14 days of once-daily dosing
Mean 4.2-fold increase in
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
